Terraflora Daily Care and Gastrointestinal Health

Purpose

A 12-week, randomized, double-blind, placebo-controlled clinical trial will be conducted evaluating the effectiveness of Enviromedica - Terraflora Daily Care on markers of gastrointestinal function and symptoms.

Condition

  • Gastrointestinal

Eligibility

Eligible Ages
Over 25 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  1. Adult males or females age ≥ 25 years 2. Ability to read and speak English 3. Dysbiosis (≥3 on GA-Map Dysbiosis Score) on a stool test (GI360 Profile, Doctor's Data, St. Charles, Illinois)

Exclusion Criteria

  1. Daily use within the past month of any probiotic or prebiotic supplement 2. Current diagnosis of inflammatory bowel disease, including Crohn's or ulcerative colitis 3. Current daily usage of non-steroidal anti-inflammatory drugs (NSAID), proton pump inhibitors (PPI), or antibiotic medications 4. Current daily tobacco smoker 5. Known allergies to any substance in the study products 6. Currently pregnant or lactating women or women planning to become pregnant in the next 12 weeks 7. Current diagnosis of any other chronic health condition (e.g., cancer, chronic kidney disease) deemed clinically contraindicated for the study protocol 8. Current participation in another clinical trial 9. Participants unable to provide consent

Study Design

Phase
N/A
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Other
Masking
Triple (Participant, Care Provider, Outcomes Assessor)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Terraflora - Daily Care
  • Dietary Supplement: Synbiotic Dietary Supplement
    12 weeks of supplementation with Enviromedica - Terraflora Daily Care
Placebo Comparator
Placebo
  • Dietary Supplement: Placebo
    Placebo capsule

Recruiting Locations

OvationLab
Richmond, Virginia 23220
Contact:
Study Administration
‪(240) 232-2103‬
info@ovationlab.com

More Details

Status
Recruiting
Sponsor
OvationLab

Study Contact

Chris D'Adamo, Ph.D.
240-232-2103
chris@ovationlab.com